Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) expects a net profit attributable to shareholders between 380 million yuan and 570 million yuan for 2024, 72% to 81% lower than 2.02 billion yuan logged for the preceding year, a Friday Hong Kong bourse filing said.
The medical laboratory company attributed the anticipated decline to a significant decrease in investment income, market competition, and a significant decrease in non-recurring gains and losses during the reporting year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.